ArticleACS omega2026
Molybdenum Nanoparticles Alleviate Psoriasis-Related Cardiovascular Oxidative Stress and Inflammation.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a common immune-mediated chronic inflammatory disease, and its impact on patients extends beyond the skin. With the continuous deepening of understanding of psoriasis, the multisystem comorbidities of psoriasis have gradually been revealed. These comorbidities include cardiovascular diseases, metabolic diseases, liver and kidney diseases, autoimmune diseases, digestive system diseases, and mental disorders, etc. Among them, the cardiovascular comorbidities of psoriasis, as they can lead to fatal myocardial infarction and affect the survival rate of patients, deserve attention. Based on previous studies, this research further explores the effect of a molybdenum nanoparticle suspension (MNS) on psoriasis-related cardiovascular inflammation. The study found that the content of ROS in the cardiovascular tissues of psoriasis model mice, the infiltration of inflammatory cells, and the expression of inflammatory mediators (TNF-α, IFN-γ, IL-1β, IL-6, and IL-17) were significantly increased, and decreased after treatment with MNS. In addition, cardiomyocyte hypertrophy observed in the model group was alleviated following MNS intervention, and the ROS/NF-κB axis may be associated with psoriasis-related cardiovascular oxidative stress and inflammation.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.